SIGA Technologies(SIGA) - 2025 Q2 - Quarterly Results

Exhibit 99.1 (1) Includes supportive services related to product sales. Key Business and Operational Activity: "In the second quarter, we achieved two positive milestones: significant product revenues and expanded development funding under the BARDA 19C contract," stated Diem Nguyen, Chief Executive Officer. "Specifically, in the second quarter, we recorded approximately $53 million of oral TPOXX sales and $26 million of IV TPOXX sales in connection with deliveries to the Strategic National Stockpile. Addit ...